Literature DB >> 23754702

Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis.

Kendra A Young1, Kevin D Deane, Lezlie A Derber, Jan M Hughes-Austin, Catriona A Wagner, Jeremy Sokolove, Michael H Weisman, Jane H Buckner, Ted R Mikuls, James R O'Dell, Richard M Keating, Peter K Gregersen, William H Robinson, V Michael Holers, Jill M Norris.   

Abstract

OBJECTIVE: To examine reactivity to anti-citrullinated protein/peptide antibodies (ACPAs) and determine associations between ACPAs and other rheumatoid arthritis (RA)-related autoantibodies and clinically assessed swollen or tender joints in unaffected first-degree relatives of RA patients.
METHODS: Serum samples were obtained from first-degree relatives without RA according to the 1987 American College of Rheumatology (ACR) and the 2010 ACR/European League Against Rheumatism classification criteria. A bead-based assay was used to measure 16 separate ACPAs in sera from 111 antibody-positive first-degree relatives who were positive on at least 1 visit for any of 5 RA-related autoantibodies (rheumatoid factor [RF], anti-cyclic citrullinated peptide 2 [anti-CCP-2], and RF isotypes), and sera from 99 antibody-negative first-degree relatives who were never autoantibody positive. Cutoffs for positivity for each ACPA were determined using receiver operating characteristic curves derived from data on 200 RA patients and 98 blood donor controls, in which positivity for ≥9 ACPAs had 92% specificity and 62% sensitivity for RA. In first-degree relatives, ACPA reactivity was assessed, and associations between ACPAs (number positive, and positivity for ≥9 ACPAs) and RA-related characteristics were examined.
RESULTS: Fifty-seven percent of anti-CCP-2-positive first-degree relatives and 8% of anti-CCP-2- negative first-degree relatives were positive for ≥9 ACPAs. After adjusting for age, sex, ethnicity, and pack-years of smoking, an increasing number of ACPAs was directly associated with the presence of ≥1 tender joint on examination (odds ratio [OR] 1.18, 95% confidence interval [95% CI] 1.04-1.34), with the greatest risk of having ≥1 tender joint seen in first-degree relatives positive for ≥9 ACPAs (OR 5.00, 95% CI 1.37-18.18).
CONCLUSION: RA-free first-degree relatives (even those negative for RF and anti-CCP-2) demonstrate reactivity to multiple ACPAs, and the presence of an increasing number of ACPAs may be associated with signs of joint inflammation. Prospective evaluation of the relationship between these findings and the progression of classifiable RA is warranted.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754702      PMCID: PMC3729718          DOI: 10.1002/art.38022

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  53 in total

1.  The antigen specificity of the rheumatoid arthritis-associated ACPA directed to citrullinated fibrin is very closely restricted.

Authors:  Cristina Iobagiu; Anna Magyar; Leonor Nogueira; Martin Cornillet; Mireille Sebbag; Jacques Arnaud; Ferenc Hudecz; Guy Serre
Journal:  J Autoimmun       Date:  2011-08-27       Impact factor: 7.094

2.  Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis.

Authors:  P Suwannalai; L A van de Stadt; H Radner; G Steiner; H S El-Gabalawy; C M Jol-van der Zijde; M J van Tol; D van Schaardenburg; T W J Huizinga; R E M Toes; L A Trouw
Journal:  Arthritis Rheum       Date:  2012-05

3.  Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies.

Authors:  F Pratesi; C Tommasi; C Anzilotti; I Puxeddu; E Sardano; G Di Colo; P Migliorini
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

4.  Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis.

Authors:  Lotte A van de Stadt; Margret H M T de Koning; Rob J van de Stadt; Gertjan Wolbink; Ben A C Dijkmans; Dörte Hamann; Dirkjan van Schaardenburg
Journal:  Arthritis Rheum       Date:  2011-11

5.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

6.  A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA.

Authors:  Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin O'Donnell; Michael H Weisman; Jane H Buckner; Vivian H Gersuk; Shan Wei; Ted R Mikuls; James O'Dell; Peter K Gregersen; Richard M Keating; Jill M Norris; V Michael Holers
Journal:  Arthritis Rheum       Date:  2009-12-15

7.  Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis.

Authors:  Mikael Brink; Monika Hansson; Linda Mathsson; Per-Johan Jakobsson; Rikard Holmdahl; Göran Hallmans; Hans Stenlund; Johan Rönnelid; Lars Klareskog; Solbritt Rantapää-Dahlqvist
Journal:  Arthritis Rheum       Date:  2013-04

8.  Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.

Authors:  Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans
Journal:  Arthritis Rheum       Date:  2004-02

9.  Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; René E M Toes; Tom W J Huizinga
Journal:  Arthritis Res Ther       Date:  2005-06-14       Impact factor: 5.156

10.  Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy.

Authors:  Pascale Nicaise Roland; Sabine Grootenboer Mignot; Alessandra Bruns; Margarita Hurtado; Elisabeth Palazzo; Gilles Hayem; Philippe Dieudé; Olivier Meyer; Sylvie Chollet Martin
Journal:  Arthritis Res Ther       Date:  2008-12-10       Impact factor: 5.156

View more
  23 in total

1.  Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody-Positive Patients Without Rheumatoid Arthritis.

Authors:  Julia A Ford; Xinyi Liu; Allison A Marshall; Alessandra Zaccardelli; Maria G Prado; Charlene Wiyarand; Bing Lu; Elizabeth W Karlson; Peter H Schur; Kevin D Deane; Jeffrey A Sparks
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-12       Impact factor: 4.794

2.  Elevated IgA Plasmablast Levels in Subjects at Risk of Developing Rheumatoid Arthritis.

Authors:  Jennifer D Kinslow; Lisa K Blum; Kevin D Deane; M Kristen Demoruelle; Yuko Okamoto; Mark C Parish; Sarah Kongpachith; Lauren J Lahey; Jill M Norris; William H Robinson; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

3.  Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.

Authors:  Yoshikazu Ogawa; Nobunori Takahashi; Atsushi Kaneko; Yuji Hirano; Yasuhide Kanayama; Yuichiro Yabe; Takeshi Oguchi; Takayoshi Fujibayashi; Hideki Takagi; Masahiro Hanabayashi; Koji Funahashi; Masatoshi Hayashi; Seiji Tsuboi; Shuji Asai; Nobuyuki Asai; Takuya Matsumoto; Yasumori Sobue; Naoki Ishiguro; Toshihisa Kojima
Journal:  Clin Rheumatol       Date:  2019-06-10       Impact factor: 2.980

Review 4.  Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.

Authors:  Kimber Simmons; Aaron W Michels
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

5.  Rheumatic diseases and the microbiome.

Authors:  Robert Hal Scofield
Journal:  Int J Rheum Dis       Date:  2014-06       Impact factor: 2.454

Review 6.  Potential of Lifestyle Changes for Reducing the Risk of Developing Rheumatoid Arthritis: Is an Ounce of Prevention Worth a Pound of Cure?

Authors:  Alessandra Zaccardelli; H Maura Friedlander; Julia A Ford; Jeffrey A Sparks
Journal:  Clin Ther       Date:  2019-06-10       Impact factor: 3.393

Review 7.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 8.  Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Curr Opin Immunol       Date:  2013-11-08       Impact factor: 7.486

Review 9.  Strategies to predict rheumatoid arthritis development in at-risk populations.

Authors:  Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil
Journal:  Rheumatology (Oxford)       Date:  2014-08-04       Impact factor: 7.580

10.  Circulating anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis and chronic obstructive pulmonary disease.

Authors:  Deng-Ho Yang; Chuan-Chou Tu; Shou-Cheng Wang; Cheng-Chung Wei; Ya-Wen Cheng
Journal:  Rheumatol Int       Date:  2013-12-24       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.